David Kirske - Jun 17, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
EVP, Chief Financial Officer
Signature
David Kirske
Stock symbol
CTIC
Transactions as of
Jun 17, 2022
Transactions value $
-$197,505
Form type
4
Date filed
6/17/2022, 04:57 PM
Previous filing
Jun 16, 2022
Next filing
Sep 20, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $10K +10K +135.19% $1.00 17.4K Jun 17, 2022 Direct
transaction CTIC common stock Sale -$60K -10K -57.48% $6.00 7.4K Jun 17, 2022 Direct F1
transaction CTIC common stock Options Exercise $165K +50K +675.95% $3.30 57.4K Jun 17, 2022 Direct
transaction CTIC common stock Sale -$313K -50K -87.11% $6.25 7.4K Jun 17, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -10K -2.86% $0.00 340K Jun 17, 2022 Common Stock 10K $1.00 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -50K -25% $0.00 150K Jun 17, 2022 Common Stock 50K $3.30 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
F2 One sixth of the shares underlying the option vested on 9/11/2020 and semi-annually thereafter until all the underlying shares will be fully vested on 3/11/2023.
F3 One sixth of the shares underlying the option vested on 9/10/2021 and semi-annually thereafter until all the underlying shares will be fully vested on 3/10/2024.